Patents by Inventor Shi-Xian Deng

Shi-Xian Deng has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20140073668
    Abstract: The present invention relates to the NQBS class of molecules. It is based, at least in part, on the discovery that a representative group of compounds have been observed to inhibit nuclear translocation of NF-?B subunits. Without being bound by any particular theory, this inhibition of nuclear translocation may be mediated by either (i) binding of the NQBS or related compound to the C-terminus of the RHD, which specifically mediates the nuclear internalization; or (ii) NQBS-mediated stabilization of the dimer/I?B complex, disallowing dissociation of the active NF-?B monomers, and thus, inhibiting the generation of the subunits necessary to enter the nucleus. The NQBS class of molecules, and related molecules, may be used in therapeutic applications where inhibition of NF-?B translocation is beneficial, including but not limited to the treatment of cancer, autoimmune disorders, and inflammatory states.
    Type: Application
    Filed: September 6, 2013
    Publication date: March 13, 2014
    Applicant: The Trustees of Columbia Unversity in the City of New York
    Inventors: Donald W. Landry, Owen O'Connor, Shi-Xian Deng, Matko Kalac, Kristen Alison Rinderspacher
  • Patent number: 8653273
    Abstract: The present invention relates to compounds that exhibit vasodilatory and anti-inflammatory effects by inhibiting the activity of soluble epoxide hydrolase (sEH). The present invention is also directed to methods of identifying such compounds, and use of such compounds for the treatment of diseases related to dysfunction of vasodilation, inflammation, and/or endothelial cells. In particular non-limiting embodiments, components of the invention may be used to treat hypertension.
    Type: Grant
    Filed: July 7, 2011
    Date of Patent: February 18, 2014
    Assignee: The Trustees of Columbia University in the city of New York
    Inventors: Kirsten Alison Rinderspacher, Donald W. Landry, Yuli Xie, Yidong Liu, Gangli Gong, Shi-Xian Deng
  • Patent number: 8614222
    Abstract: The present invention provides methods and therapeutic agents for lowering or increasing serum serotonin levels in a patient in order to increase or decrease bone mass, respectively. In preferred embodiments, the patient is known to have, or to be at risk for, a low bone mass disease such as osteoporosis and the agents are TPH1 inhibitors or serotonin receptor antagonists.
    Type: Grant
    Filed: November 13, 2009
    Date of Patent: December 24, 2013
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: Gerard Karsenty, Patricia F. Ducy, Vijay Kumar Yadav, Donald Landry, Shi-Xian Deng
  • Publication number: 20130225592
    Abstract: The present invention relates to novel compounds and pharmaceutical compositions thereof, and methods for promoting healthy aging of skin, the treatment of skin disorders, the treatment of cardiovascular disorders, the treatment of renal disorders, the treatment of angiogenesis disorders, such as cancer, treatment of tissue damage, such as non-cardiac tissue damage, the treatment of evolving myocardial infarction, and the treatment of various other disorders, such as complications arising from diabetes with the compounds and compositions of the invention. Other disorders can include, but are not limited to, atherosclerosis, coronary artery disease, diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, infections of the skin, peripheral vascular disease, stroke, and the like.
    Type: Application
    Filed: January 16, 2013
    Publication date: August 29, 2013
    Inventors: Andrew WASMUTH, Donald W. LANDRY, Shi Xian DENG, Ravichandran RAMASAMY, Ann Marie SCHMIDT, Banavara L. MYLARI
  • Publication number: 20130121919
    Abstract: The invention provides for a method for screening compounds that bind to and modulate a histone acetyltransferase protein. The invention further provides methods for treating neurodegenerative disorders, conditions associated with accumulated amyloid-beta peptide deposits, Tau protein levels, and/or accumulations of alpha-synuclein as well as cancer by administering a HAT-activating compound to a subject.
    Type: Application
    Filed: June 11, 2012
    Publication date: May 16, 2013
    Applicant: The Trustees of Columbia University in the City of New York
    Inventors: Yan FENG, Mauro Fa, Ottavio Arancio, Shi Xian Deng, Donald W. Landry, Yitshak Francis
  • Publication number: 20130053343
    Abstract: Compounds having the structures below that are TPH1 inhibitors are provided: The compounds are useful of, e.g., to increase bone mass. In preferred embodiments, the patient is known to have, or to be at risk for, a low bone mass disease such as osteoporosis.
    Type: Application
    Filed: November 2, 2010
    Publication date: February 28, 2013
    Applicant: The Trustees of Columbia University in th City of
    Inventors: Donald Landry, Shi-Xian Deng
  • Patent number: 8318156
    Abstract: Embodiments of the invention disclosed herein generally relate to anti-cocaine therapeutics. Specifically, some embodiments of the invention relate to highly efficient, thermostable, and long-lasting cocaine esterase (CocE) mutants that can protect against the toxic and reinforcing effects of cocaine in subjects. Provided herein are mutant CocE polypeptides displaying thermostable esterase activity. Also provided are methods of treating cocaine-induced conditions in a subject in need via administration of mutant CocE as well as methods for high-throughput screening of candidate esterase polypeptides.
    Type: Grant
    Filed: July 10, 2007
    Date of Patent: November 27, 2012
    Assignees: The Trustees of Columbia University in the City of New York, The Regents of the University of Michigan, University of Kentucky Research Foundation
    Inventors: Donald W Landry, Joanne MacDonald, Shi-Xian Deng, Chang-Guo Zhan, Daquan Gao, James H. Woods, Roger K. Sunahara, Diwahar L. Narasimhan, Victor Yang, Mei-Chuan Holden Ko, John J. Tesmer, Tien-Yi Lee, Young Min Kwon
  • Publication number: 20120295853
    Abstract: The present invention relates to the discovery of a novel molecular pathway involved in long-term hyperexcitability of sensory neurons, which, in higher animals, is associated with persistent pain. It is based on the discovery that, following injury to an axon of a neuron, an increase in nitric oxide synthase activity results in increased nitric oxide production, which, in turn, activates guanylyl cyclase, thereby increasing levels of cGMP. Increased cGMP results in activation of protein kinase G (“PKG”), which then is retrogradely transported along the axon to the neuron cell body, where it phosphorylates MAPKerk.
    Type: Application
    Filed: August 8, 2012
    Publication date: November 22, 2012
    Inventors: Richard Ambron, Ying-Ju Sung, Donald W. Landry, Shi-Xian Deng
  • Publication number: 20120269828
    Abstract: The present invention relates to anti-drug vaccines based on conjugates between the drug and a non-immunogenic carrier protein. In preferred embodiments, it provides for anti-cocaine vaccines and their use to diminish the effects and/or use of cocaine in a subject.
    Type: Application
    Filed: April 20, 2012
    Publication date: October 25, 2012
    Applicant: The Trustees of Columbia University in the City of New York
    Inventors: Shi-Xian Deng, Donald W. Landry, Gavreel Kalantarov, Trakht IIya
  • Patent number: 8252754
    Abstract: The present invention relates to the discovery of a novel molecular pathway involved in long-term hyperexcitability of sensory neurons, which, in higher animals, is associated with persistent pain. It is based on the discovery that, following injury to an axon of a neuron, an increase in nitric oxide synthase activity results in increased nitric oxide production, which, in turn, activates guanylyl cyclase, thereby increasing levels of cGMP. Increased cGMP results in activation of protein kinase G (“PKG”), which then is retrogradely transported along the axon to the neuron cell body, where it phosphorylates MAPKerk.
    Type: Grant
    Filed: March 21, 2006
    Date of Patent: August 28, 2012
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: Richard Ambron, Ying-Ju Sung, Donald W. Landry, Shi-Xian Deng
  • Publication number: 20120064099
    Abstract: The present invention relates to compounds with activity as BACE1 and NF?B modulators, and methods for treating, preventing, or ameliorating neurodegenerative diseases, such as Alzheimer's disease. The present invention is also directed to the treatment of diseases related to dysfunction of cell proliferation, the immune system and/or inflammation using such compounds or pharmaceutical compositions containing such candidate compounds.
    Type: Application
    Filed: April 26, 2011
    Publication date: March 15, 2012
    Applicant: The Trustees of Columbia University in The City of New York
    Inventors: Donald W. Landry, Tae-Wan Kim, Shi Xian Deng, Gangli Gong, Jeremy C. Hwang, Yuli Xie, Yidong Liu, K. Alison Rinderspacher
  • Publication number: 20120029022
    Abstract: The present invention relates to compounds that exhibit vasodilatory and anti-inflammatory effects by inhibiting the activity of soluble epoxide hydrolase (sEH). The present invention is also directed to methods of identifying such compounds, and use of such compounds for the treatment of diseases related to dysfunction of vasodilation, inflammation, and/or endothelial cells. In particular non-limiting embodiments, components of the invention may be used to treat hypertension.
    Type: Application
    Filed: July 7, 2011
    Publication date: February 2, 2012
    Applicant: The Trustees Of Columbia Univesity In The City Of New York
    Inventors: Donald W. Landry, Yuli Xie, Yidong Liu, Gangli Gong, Shi-Xian Deng, Kirsten Alison Rinderspacher
  • Publication number: 20110281899
    Abstract: The present invention provides methods and therapeutic agents for lowering or increasing serum serotonin levels in a patient in order to increase or decrease bone mass, respectively. In preferred embodiments, the patient is known to have, or to be at risk for, a low bone mass disease such as osteoporosis and the agents are TPH1 inhibitors or serotonin receptor antagonists.
    Type: Application
    Filed: November 13, 2009
    Publication date: November 17, 2011
    Applicant: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
    Inventors: Gerard Karsenty, Patricia F. Ducy, Vijay Kumar Yadav, Donald Landry, Shi-Xian Deng
  • Publication number: 20110071124
    Abstract: The present invention relates to compounds with activity as inhibitors of sAPP? and A? production, and methods for treating, preventing, or ameliorating neurodegenerative diseases, such as Alzheimer's disease and pharmaceutical compositions containing such candidate compounds.
    Type: Application
    Filed: August 18, 2010
    Publication date: March 24, 2011
    Applicant: The Trustees of Columbia University in the City of New York
    Inventors: Tae-wan Kim, Donald W. Landry, Jeremy C. Hwang, Shi Xian Deng, Gangli Gong, Yuli Xie, Yidong Liu, Alison Rinderspacher
  • Publication number: 20100204258
    Abstract: The present invention relates to methods and compositions for treating or ameliorating the effects of diabetes. In addition, the present invention relates to methods and compositions for treating or preventing hyperglycemia, as well as modulating monoamine levels, islet ?-cell insulin secretion, insulin and/or glucagon levels in a patient. In certain preferred embodiments, such methods include administering to a patient an effective amount of a vesicular monoamine transporter type 2 (VMAT2) antagonist, such as tetrabenazine (TBZ), dihydrotetrabenazine (DTBZ), tetrahydroberberine (THB), reserpine, emetine, Compound 6, or enantiomers, optical isomers, diastereomers, N-oxides, crystalline forms, hydrates, metabolites or pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: March 12, 2008
    Publication date: August 12, 2010
    Applicant: The Trustees of Columbia University in the City of New York
    Inventors: Paul Harris, Yuli Xie, Donald Landry, Shi-Xian Deng, Antonella Maffei
  • Publication number: 20100152440
    Abstract: The present invention provides novel 1,4-benzothiazepine intermediates and derivatives, methods for synthesizing same, and methods for assaying same. The present invention also provides methods for using these novel compounds to limit or prevent a decrease in the level of RyR2-bound FKBP12.6 in a subject; to prevent exercise-induced sudden cardiac death in a subject; and to treat or prevent heart failure, atrial fibrillation, or exercise-induced cardiac arrhythmia in a subject. The present invention further provides methods for identifying an agent that enhances binding of RyR2 and FKBP12.6, and agents identified by these methods. Additionally, the present invention provides methods for identifying agents for use in treating or preventing heart failure, atrial fibrillation, or exercise-induced cardiac arrhythmia, and in preventing exercise-induced sudden cardiac death. Also provided are agents identified by such methods.
    Type: Application
    Filed: June 8, 2009
    Publication date: June 17, 2010
    Inventors: Andrew Robert Marks, Donald W. Landry, Shi Xian Deng, Zhen Zhuang Cheng
  • Publication number: 20100034799
    Abstract: Embodiments of the invention disclosed herein generally relate to anti-cocaine therapeutics. Specifically, some embodiments of the invention relate to highly efficient, thermostable, and long-lasting cocaine esterase (CocE) mutants that can protect against the toxic and reinforcing effects of cocaine in subjects. Provided herein are mutant CocE polypeptides displaying thermostable esterase activity. Also provided are methods of treating cocaine-induced conditions in a subject in need via administration of mutant CocE as well as methods for high-throughput screening of candidate esterase polypeptides.
    Type: Application
    Filed: July 10, 2007
    Publication date: February 11, 2010
    Inventors: Donald Landry, Chang-Guo Zhan, James H. Woods, Roger Sunahara, Diwahar L. Narasimhan, Joanne MacDonald, Victor Yang, Mei-Chuan Holden Ko, Shi-Xian Deng, John J. Tesmer, Tien-Yi Lee, Young Min Kwon, Daquan Gao
  • Publication number: 20080176920
    Abstract: The present invention relates to compounds that may be used to inhibit activation of protein kinase G (“PKG”). It is based, at least in part, on the discovery of the tertiary structure of PKG and the identification of molecules that either bind to the active site of PKG and/or are analogs of balanol.
    Type: Application
    Filed: February 14, 2007
    Publication date: July 24, 2008
    Inventors: Richard Ambron, Ying-Ju Sung, Jeremy Greenwood, Leah Frye, Shi-Xian Deng, Yuli Xie, Donald W. Landry
  • Patent number: 7348403
    Abstract: This invention provides methods and peptides for the inactivation of organophosphorus-based insecticides and chemical warfare agents. The instant methods include peptide screening methods, peptides and peptide libraries, related compositions of matter, articles of manufacture, and methods for prophylaxis, treatment, decontamination and detection.
    Type: Grant
    Filed: December 8, 2003
    Date of Patent: March 25, 2008
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: Donald W. Landry, Shi-Xian Deng
  • Publication number: 20060216778
    Abstract: This invention provides methods and peptides for the inactivation of organophosphorus-based insecticides and chemical warfare agents. The instant methods include peptide screening methods, peptides and peptide libraries, related compositions of matter, articles of manufacture, and methods for prophylaxis, treatment, decontamination and detection.
    Type: Application
    Filed: December 8, 2003
    Publication date: September 28, 2006
    Inventors: Donald Landry, Shi-Xian Deng